Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Colorectal Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplasms 1Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Pancreatic Ductal Adenocarcinoma (PDAC) × 30 days × Clear all
NCT07612930 2026-05-29

Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy

Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.

Available
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡